Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...

Related Keywords

United States ,Paris ,France General ,France ,Chicago ,Illinois ,America ,American ,Jeff Legos ,Julie Masow ,Jamie Bennett ,Sloan Simpson ,Catherine Thieblemont ,Fiona Phillips ,Prnewswire Novartis ,American Society Of Clinical Oncology ,Twitter ,Paris University ,Follicular Lymphoma International Prognostic Index ,Novartis Oncology Communications ,Perelman School Of Medicine ,Novartis ,Exchange Commission ,Global Head Of Oncology Hematology Development ,American Society Of Hematology ,Nj Novartis Pharmaceuticals Corporation ,University Of Pennsylvania ,American Society Of Hematology Annual Meeting Exposition ,American Society ,Hematology Annual Meeting ,Hemato Oncology Unit ,St Louis Hospital ,Executive Vice President ,Global Head ,Hematology Development ,Oncology Cell ,Perelman School ,Cytokine Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Prescribing Information ,Medication Guide ,East Hanover ,Pharmaceuticals Corporation ,Adult Patients ,Refractory Follicular Lymphoma ,Subgroup Analysis ,Annual Meeting ,Healthcare Resource Utilization ,Refractory Follicular Lymphoma Undergoing ,Lymphoma Classification ,Ther Adv ,Primary Analysis ,Clinical Oncology ,Novartis Us ,